permeabilization reagent medium b (Thermo Fisher)

Thermo Fisher is a verified supplier

Thermo Fisher manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Thermo Fisher permeabilization reagent medium b
Permeabilization Reagent Medium B, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/permeabilization+medium+(reagent+b/permeabilization+medium+b/pmc09408523-168-54-58
Average 90 stars, based on 1 article reviews

permeabilization reagent medium b - by Bioz Stars, 2026-09

90/100 stars

Images

Single Cell:

Article Title: Human Umbilical Cord Lining-Derived Epithelial Cells: A Potential Source of Non-Native Epithelial Cells That Accelerate Healing in a Porcine Cutaneous Wound Model
Article Snippet: .. Single-cell suspensions were fixed with Fixation Reagent (Medium A; Life Technologies, Thermo Fisher Scientific, Frederick, MD, USA) for 15 min at room temperature (RT), washed with FC buffer (0.5% bovine serum albumin and 2 mM EDTA in 1× PBS), blocked with 5% goat serum in FC buffer and then immunostained with primary antibodies in Permeabilization Reagent (Medium B; Life Technologies) for 15 min at RT. ..

Labeling:

Article Title: The Impact of Different Anesthetics on the Distribution and Cytotoxic Function of NK Cell Subpopulations: An In Vitro Study
Article Snippet: Next, the cells were fixed with 100 μL of fixation reagent A (Fix/Perm medium A, Thermo Fisher Scientific, Waltham, MA, USA) for 15 min at room temperature in the dark. .. After washing, the cells were resuspended in 100 μL of permeabilization reagent B (Fix/Perm medium B, Thermo Fisher Scientific) and labeled with anti-human GrzB Alexa647 (BD Biosciences) and anti-human Perforin Brilliant Violet 421 (BD Biosciences) for 30 min at room temperature in the dark. .. The cells were washed and analyzed using an LSR-II flow cytometer (BD).

other:

Article Title: Angiogenic stem cell delivery platform to augment post-infarction neovasculature and reverse ventricular remodeling.
Article Snippet: After two washes with staining buffer, the SMCs were incubated with a permeabilization medium (Reagent B of FIX & PERMTM Cell Permeabilization Kit; Thermo Fisher Scientific, MA, USA) and three intracellular antibodies on ice for 30 min in the dark: PE-conjugated α-SMA (1:100, Abcam, Cambridge, UK; Cat: ab209435), APC-conjugated SM22-α (1:100, Abcam, Cambridge, UK; Cat: ab14106 (the primary antibody was conjugated using Lightning-Link APC labeling kit; Novus Biologicals LLC, CO, USA)), and AF700-conjugated caldesmon (1:100, Novus Biologicals LLC, CO, USA; Cat: NBP2-47819AF700).

Article Title: Generation, functional analysis and applications of isogenic three-dimensional self-aggregating cardiac microtissues from human pluripotent stem cells
Article Snippet: ● BSA (Sigma-Aldrich, cat. no. A3311) ● Fetal bovine serum (FBS; Thermo Fisher Scientific, cat. no. 10270-106) ● Fixation medium (Reagent A; Thermo Fisher Scientific, cat. no. GAS001S5) ● Permeabilization medium (Reagent B; Thermo Fisher Scientific, cat. no. GAS002S5) ● Sodium-L-lactate (Sigma-Aldrich, cat. no. 71718) ● Dimethyl sulfoxide (DMSO; Sigma-Aldrich, cat. no. D2650) !

Article Title: Naturally aligned cell delivery platform to augment post-infarction neovasculature and ventricular remodeling
Article Snippet: After two washes with staining buffer, the SMCs were incubated with permeabilization medium (Reagent B of FIX & PERMTM Cell Permeabilization Kit; Thermo Fisher Scienti c, MA, USA) and three intracellular antibodies on ice for 30 min in the dark: PE-conjugated α-SMA (1:100, Abcam, Cambridge, UK; Cat: ab209435), APC-conjugated SM22-α (1:100, Abcam, Cambridge, UK; Cat: ab14106 (the primary antibody was conjugated using Lightning-Link APC labeling kit; Novus Biologicals LLC, CO, USA), and AF700conjugated caldesmon (1:100, Novus Biologicals LLC, CO, USA; Cat: NBP2-47819AF700).

Staining:

Article Title: Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Article Snippet: Purpose Patients with heterozygous gain-of-function (GOF) mutations in STAT1 frequently exhibit chronic mucocutaneous candidiasis (CMC), immunodeficiency and autoimmune manifestations.. Several treatment options including targeted therapies and hematopoietic stem cell transplantation (HSCT) are available for STAT1 GOF patients but modalities and outcomes are not well established.. Herein, we aimed to unravel the effect of ruxolitinib as a bridge therapy in a patient with sporadic STAT1T385M mutation to manage infections and other disease manifestations.

Review